Actively Recruiting
Assessing 68Ga-ABS011 PETCT Imaging for HER2 Status in Metastatic Breast Cancer and Other Solid Tumors
Led by Abscint NV/SA · Updated on 2026-10-27
60
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the diagnostic accuracy of a new imaging agent called 68Ga-ABS011 PETCT in detecting HER2 expression status in patients with metastatic breast cancer mBC and other metastatic solid carcinomas. The study compares this new imaging approach with standard diagnostic methods such as immunohistochemistry IHC, in situ hybridization ISH, and imaging techniques like 18F-FDG PET and contrast-enhanced CT ceCT. This phase II trial aims to improve the detection of HER2 status and to assess the impact of 68Ga-ABS011 on treatment decisions. The investigational agent 68Ga-ABS011 is a labeled single domain antibody that binds quickly to HER2 tumor antigens and clears rapidly from the blood, allowing for whole-body PETCT imaging with low radiation exposure. Participants with hormone receptor positiveHER2 negative, triple-negative, or HER2 positive metastatic breast cancer will undergo 68Ga-ABS011 PETCT after completing an 18F-FDG PETCT and lesion biopsy. The study evaluates 68Ga-ABS011s ability to identify tumor heterogeneity and changes in treatment management immediately after imaging. Participants will undergo imaging assessments, tumor biopsies, and standard diagnostic procedures. Researchers will measure diagnostic agreement between 68Ga-ABS011 PETCT and standard tests, safety of the imaging agent, and treatment changes. Outcomes also include evaluating tumor heterogeneity and the reliability of 68Ga-ABS011 PETCT in tracking treatment response six weeks after starting HER2-targeted therapy. The study involves monitoring up to six weeks after treatment initiation, with participation expected to last until study completion in late 2026.
CONDITIONS
Brief Title
HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
Research Team
K
Karine Clauwaert
D
Dieter Frijns
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here